Coya Therapeutics, Inc. Stock Price, News & Analysis

Coya Therapeutics (Nasdaq: COYA) has completed a $10.0 million private placement through the sale of 1,379,314 shares of common stock at $7.25 per share. The majority of investors were existing institutional stockholders. As of September 30, 2024, the company reported preliminary unaudited cash and cash equivalents of approximately $31.0 million. The proceeds will support general corporate purposes, administrative expenses, working capital, and preclinical, clinical, and regulatory activities for their product pipeline. BTIG, led the placement, with Allele Capital Partners and Chardan as co-placement agents.

Coya Therapeutics (Nasdaq: COYA), a clinical-stage biotechnology company focused on enhancing regulatory T cell function, has announced a $10.0 million private placement. The company will sell 1,379,314 shares of common stock at $7.25 per share to primarily existing institutional stockholders. The offering is expected to close around October 23, 2024, subject to customary conditions.

BTIG, is leading the placement, with Allele Capital Partners, and Chardan Capital Markets as co-placement agents. Coya plans to use the net proceeds for general corporate purposes, including administrative expenses, working capital, and supporting preclinical, clinical, and regulatory activities for their product pipeline.

The securities are being offered privately under Section 4(a)(2) of the Securities Act and Regulation D, and are not registered for public sale. Coya has agreed to file a registration statement with the SEC for resale of these securities within 30 days of the definitive agreements.

Coya Therapeutics (NASDAQ: COYA) announces that its Chairman and CEO, Howard Berman, Ph.D., has been recognized as a PharmaVoice 100 winner in the category of Biotech Pathfinders. This annual list honors the most inspiring individuals in the life sciences industry. The recognition comes as Dr. Berman prepares to transition to Executive Chairman on Nov. 1, as previously announced.

Arun Swaminathan, Ph.D., Coya's current Chief Business Officer and incoming CEO, praised Dr. Berman's leadership in building Coya from a startup to a clinical-stage company with promising candidates for neurodegenerative diseases. The PharmaVoice 100 honors individuals across various categories, recognizing their transformative impact on the pharmaceutical industry.

Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company focused on enhancing regulatory T cell (Treg) function, has announced its participation in the Chardan 8th Annual Genetic Medicines Conference. The event will take place on September 30 – October 1, 2024, at the Westin Grand Central in New York City.

CEO Howard Berman, Ph.D. and Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D, will engage in a fireside chat on Tuesday, October 1, 2024, at 2:00pm ET. The discussion will be moderated by Keay Nakae, Senior Research Analyst at Chardan Capital Markets. Both executives will also be available for one-on-one meetings throughout the conference.

Coya Therapeutics (NASDAQ: COYA) announces promising results for COYA 302, a subcutaneously administered anti-inflammatory biologic, in a preclinical Parkinson's disease (PD) mouse model. The study shows that COYA 302 significantly reduces neuroinflammation in key brain regions affected by PD, including:

• Decreased microglial activation in the nigrostriatal pathway
• Reduced astrocyte numbers and activation (astrogliosis)

These findings suggest that COYA 302 can directly modulate brain inflammation when administered peripherally, potentially offering a new therapeutic approach for PD and other neurodegenerative diseases like Alzheimer's and Frontotemporal Dementia. The company plans to present or publish these results in a peer-reviewed setting.

Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on enhancing regulatory T cell function, announces CEO Howard Berman's participation in two upcoming healthcare conferences. On September 26, 2024, Dr. Berman will join a panel discussion at Munsch Hardt's 3rd Annual Texas Health Care Transactions Conference in Houston. On October 28, 2024, Dr. Berman and Dr. Stanley Appel will present data on COYA 302 at the inaugural Alzheimer's Drug Discovery Foundation (ADDF) Summit in Madrid, Spain.

The company will also present results from a Gates Foundation and Alzheimer's Association funded study on low-dose interleukin-2 in Alzheimer's patients at the Clinical Trials on Alzheimer's Disease conference. In May 2024, Coya received a $5 million strategic equity investment from ADDF to support COYA 302's development for Frontotemporal Dementia treatment.

Coya Therapeutics (NASDAQ: COYA) has announced a leadership transition, with Arun Swaminathan Ph.D. promoted to Chief Executive Officer effective November 1, 2024. Dr. Howard Berman, the company's founder, will transition to Executive Chair of the Board. Dr. Swaminathan, who joined Coya as Chief Business Officer in April 2023, has been instrumental in executing several significant commercial transactions, including Coya's recent $700 million licensing deal with Dr. Reddy's Laboratories.

The company is preparing for the release of Alzheimer's data at the CTAD24 conference on October 29, 2024, and continues to progress COYA 302 in ALS. Coya believes Dr. Swaminathan's experience will be valuable in advancing COYA 302 in related programs such as Frontotemporal Dementia, Parkinson's Disease, and other immune-mediated diseases.

Coya Therapeutics (Nasdaq: COYA) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:

1. Received a $5 million investment from the Alzheimer's Drug Discovery Foundation for COYA 302 development in Frontotemporal Dementia.

2. Obtained $3.85 million from Dr. Reddy's Laboratories for COYA 302's Phase 2 ALS trial.

3. Published promising Phase 1 results for CTLA4-Ig and IL-2 combination in ALS patients.

4. Expanded research collaboration with Houston Methodist Research Institute.

5. Filed new U.S. patents for COYA 301 in combination with GLP-1 receptor agonists.

6. Q2 2024 financials: $36.6 million cash on hand, R&D expenses of $4.6 million, and net loss of $2.9 million.

Coya Therapeutics (NASDAQ: COYA) has announced that results from a double-blind, placebo-controlled phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease will be presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid on October 29, 2024. The study, conducted at Houston Methodist Research Institute and supported by the Gates Foundation and Alzheimer's Association, evaluated 38 patients over 30 weeks. This presentation replaces the previously announced topline data release planned for Summer 2024. A prior open-label study showed that low-dose IL-2 was well-tolerated and resulted in significant improvements in cognitive function and regulatory T cell (Treg) function and numbers in AD patients.